Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study - PubMed
5 hours ago
- #renal cell carcinoma
- #combination therapy
- #real-world evidence
- Pembrolizumab plus lenvatinib showed a significantly higher objective response rate compared to axitinib-based regimens as first-line therapy for metastatic clear cell renal cell carcinoma.
- Adverse event rates were similar overall, but pembrolizumab-lenvatinib was associated with higher rates of specific side effects like hypertension, fatigue, appetite loss, and rash in the full-dose subgroup.
- Progression-free survival and overall survival did not differ significantly between the treatment regimens; survival outcomes were linked to clinical factors rather than the regimen type.
- The study concluded that pembrolizumab-lenvatinib offers superior tumor response, but treatment selection should balance efficacy with differences in toxicity profiles.